Clinical trial program of nadofaragene firadenovec in NMIBC expands
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
The approval was based on data from three phase 3 trials which compared the efficacy of different dosing regimens of pivmecillinam to placebo, to another…
Researchers conducted a systematic review and meta-analysis to assess the relationship between GLP-1RA treatment and blood pressure effects.
“It’s a system that is still not being used to its maximum capability, which is exciting. That means we can continue evolving,” says Jaschar Shakuri-Rad,…
prostate cancer, Brief Androgen Suppression and Stereotactic Radiation Therapy, High-Risk Prostate Cancer, FASTR trial, FASTR-2 Trials, stereotactic ablative radiotherapy (SABR), SABR in high-risk prostate cancer.
The Institute for Leadership & Business (ILB) Track features seven courses bundled into one convenient package and offered over 4 days. Includes both in-person and…
Researchers explored which dietary components affect gout risk and identified factors that mediated these associations.
The first patient was treated with TLX250-CDx at the Olivia Newton-John Cancer Wellness Centre at Austin Health in Melbourne, Australia,
Massimo (Max) Loda discusses his team’s research on the role of the microenvironment in prostate cancer progression, published in Nature Communications. The study focuses on…